ID
24787
Descrizione
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Keywords
versioni (4)
- 17/08/17 17/08/17 -
- 23/08/17 23/08/17 -
- 04/09/17 04/09/17 -
- 04/09/17 04/09/17 -
Titolare del copyright
GlaxoSmithKline
Caricato su
17 agosto 2017
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Similar models
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
C0011008 (UMLS CUI [1,2])